Cyber attacks are a constant threat for organisations, with most facing the question of when, not if, they will be targeted. Just as businesses adopt new technology and processes to harden their ...
Hosted on MSN
Top cyber attack vectors organisations face
Cyber crime is now the number one global business risk. Cyber attacks are a constant threat for organisations, with most facing the question of when, not if, they will be targeted. Just as businesses ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...
FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...
After military service a career as war correspondent was on the cards. But then an exclusive bursar programme in automotive journalism came 'a-knockin' - and so a 26-year journey spanning newspapers, ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
We continue to enhance DevExpress-related learning materials/examples on GitHub. Unfortunately, this example lacked user interest and its code base is now obsolete. If the use-case outlined in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback